Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
Battelino T, Danne T, Edelman SV, Choudhary P, Renard E, Westerbacka J, Mukherjee B, Pilorget V, Coudert M, Bergenstal RM. Battelino T, et al. Among authors: choudhary p. Diabetes Obes Metab. 2023 Feb;25(2):545-555. doi: 10.1111/dom.14898. Epub 2022 Nov 14. Diabetes Obes Metab. 2023. PMID: 36263928 Free PMC article. Clinical Trial.
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. Battelino T, et al. Among authors: choudhary p. Diabetes Ther. 2020 Apr;11(4):1017-1027. doi: 10.1007/s13300-020-00781-6. Epub 2020 Feb 25. Diabetes Ther. 2020. PMID: 32100192 Free PMC article.
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. Battelino T, et al. Among authors: choudhary p. Diabetes Ther. 2020 Jul;11(7):1607-1608. doi: 10.1007/s13300-020-00820-2. Diabetes Ther. 2020. PMID: 32361833 Free PMC article.
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. Battelino T, et al. Among authors: choudhary p. Diabetes Ther. 2020 Aug;11(8):1907-1908. doi: 10.1007/s13300-020-00853-7. Diabetes Ther. 2020. PMID: 32578133 Free PMC article.
Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time-in-ranges with the desired precision.
Camerlingo N, Vettoretti M, Sparacino G, Facchinetti A, Mader JK, Choudhary P, Del Favero S; on behalf of the Hypo-RESOLVE Consortium. Camerlingo N, et al. Among authors: choudhary p. Diabetes Obes Metab. 2021 Nov;23(11):2446-2454. doi: 10.1111/dom.14483. Epub 2021 Jul 21. Diabetes Obes Metab. 2021. PMID: 34212483 Free PMC article.
597 results